An Open-label Study to Assess the Safety and Tolerability of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2013 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 17 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.